Pharmacogenomics suggests new treatment approach for leukaemia.
Senior
Kathryn
K
D002227:Carbazoles / Q000627:therapeutic use; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005663:Furans; D020440:Gene Duplication; D006801:Humans; D007211:Indoles; D007938:Leukemia / Q000235:genetics / Q000628:therapy*; D009154:Mutation; D010597:Pharmacogenetics / Q000379:methods*; D011518:Proto-Oncogene Proteins / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D051941:fms-Like Tyrosine Kinase 3
D002227:Carbazoles; D004791:Enzyme Inhibitors; D005663:Furans; D007211:Indoles; D011518:Proto-Oncogene Proteins; C119379:lestaurtinib; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3